Activin and Inhibin

IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1) . IDH889 has potent selectivity for IDH1 R132* mutations, with IC 50 s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H ,

IDO-IN-12 is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO 2017181849 A1.Form:SolidIC50&amp: Target:IDO.

IDO-IN-12 is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO 2017181849 A1.Form:SolidIC50&amp: Target:IDO.

IDO-IN-12 is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO 2017181849 A1.Form:SolidIC50&amp: Target:IDO.

IDO-IN-12 is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO 2017181849 A1.IC50&amp: Target:IDO.

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase ( IDO ) inhibitor with an IC 50 of 290 nM.In VitroIDO-IN-3 (Compound 4c) is a potent (HeLa IC 50 =98 nM) inhibitor of IDO. MCE has not independently confirmed the accuracy of these methods. They are

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase ( IDO ) inhibitor with an IC 50 of 290 nM.In VitroIDO-IN-3 (Compound 4c) is a potent (HeLa IC 50 =98 nM) inhibitor of IDO. MCE has not independently confirmed the accuracy of these methods. They are

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase ( IDO ) inhibitor with an IC 50 of 290 nM.In VitroIDO-IN-3 (Compound 4c) is a potent (HeLa IC 50 =98 nM) inhibitor of IDO. MCE has not independently confirmed the accuracy of these methods. They are

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase ( IDO ) inhibitor with an IC 50 of 290 nM.In VitroIDO-IN-3 (Compound 4c) is a potent (HeLa IC 50 =98 nM) inhibitor of IDO. MCE has not independently confirmed the accuracy of these methods. They are

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase ( IDO ) inhibitor with an IC 50 of 290 nM.In VitroIDO-IN-3 (Compound 4c) is a potent (HeLa IC 50 =98 nM) inhibitor of IDO. MCE has not independently confirmed the accuracy of these methods. They are

IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC 50 of 1-10 μM.In VitroIDO-IN-5 (Compound 1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC 50

IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase ( IDO ) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC 50 of 1-10 μM.In VitroIDO-IN-5 (Compound 1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC 50